Skip to main content
. 2013 Oct 25;53(11):797–804. doi: 10.2176/nmc.oa2013-0195

Table 3.

Follow-up period and median progression-free and overall survival

MPV3 (n = 23) MTX5 (n = 15) Log-rank test results
Follow-up period (m) 39 (7–72) 23 (6–37)
Median PFS (m) 12 N.R. 0.01
Median OS (m) 39 N.R. 0.01

M: month, MPV: methotrexate + procarbazine + vincristine, MTX: methotrexate, N.R.: not reached, OS: overall survival, PFS: progression-free survival.